Luigi E. Grimaldi

Rome, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications

Subcutaneous natalizumab administration in relapsing-remitting multiple sclerosis: results of EASIER 2 study.

Subcutaneous natalizumab administration in relapsing-remitting multiple sclerosis: results of EASIER 2 study.

Journal: Journal of neurology
Published: March 19, 2026

Reduced Childhood Outdoor Exposure Raises Pediatric Multiple Sclerosis (PedMS) Risk.

Reduced Childhood Outdoor Exposure Raises Pediatric Multiple Sclerosis (PedMS) Risk.

Journal: Neurology and therapy
Published: February 16, 2026

Comparative Effectiveness of Cladribine and S1P Receptor Modulators in Treatment-Naive Relapsing-Remitting MS.

Comparative Effectiveness of Cladribine and S1P Receptor Modulators in Treatment-Naive Relapsing-Remitting MS.

Journal: JAMA network open
Published: November 03, 2025

Reducing Early-Life Smoke Exposure as a Preventive Strategy for Pediatric Multiple Sclerosis: Results from the PEDIGREE Study.

Reducing Early-Life Smoke Exposure as a Preventive Strategy for Pediatric Multiple Sclerosis: Results from the PEDIGREE Study.

Journal: Neurology and therapy
Published: October 29, 2025

Efficacy and safety of ublituximab for relapsing multiple sclerosis patients: current evidence and expert opinion.

Efficacy and safety of ublituximab for relapsing multiple sclerosis patients: current evidence and expert opinion.

Journal: Journal of neurology
Published: July 28, 2025

Treatment modifiers across different regimens of natalizumab treatment in MS: An Italian real-world experience.

Treatment modifiers across different regimens of natalizumab treatment in MS: An Italian real-world experience.

Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Published: September 25, 2023

Intravenous or subcutaneous natalizumab in patients with relapsing-remitting multiple sclerosis: investigation on efficiency and savings-the EASIER study.

Intravenous or subcutaneous natalizumab in patients with relapsing-remitting multiple sclerosis: investigation on efficiency and savings-the EASIER study.

Journal: Journal of neurology
Published: July 19, 2023

Antibody response elicited by the SARS-CoV-2 vaccine booster in patients with multiple sclerosis: Who gains from it?

Antibody response elicited by the SARS-CoV-2 vaccine booster in patients with multiple sclerosis: Who gains from it?

Journal: European journal of neurology
Published: February 10, 2023

Unmet needs and gaps in the identification of secondary progression in multiple sclerosis: a Southern Italy healthcare professionals' perspective.

Unmet needs and gaps in the identification of secondary progression in multiple sclerosis: a Southern Italy healthcare professionals' perspective.

Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Published: June 08, 2022

Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study.

Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study.

Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Published: March 28, 2022

Radiomics Analysis of Brain [18F]FDG PET/CT to Predict Alzheimer's Disease in Patients with Amyloid PET Positivity: A Preliminary Report on the Application of SPM Cortical Segmentation, Pyradiomics and Machine-Learning Analysis.

Radiomics Analysis of Brain [18F]FDG PET/CT to Predict Alzheimer's Disease in Patients with Amyloid PET Positivity: A Preliminary Report on the Application of SPM Cortical Segmentation, Pyradiomics and Machine-Learning Analysis.

Journal: Diagnostics (Basel, Switzerland)
Published: March 08, 2022

Subcutaneous Uptake on [18F]Florbetaben PET/CT: a Case Report of Possible Amyloid-Beta Immune-Reactivity After COVID-19 Vaccination.

Subcutaneous Uptake on [18F]Florbetaben PET/CT: a Case Report of Possible Amyloid-Beta Immune-Reactivity After COVID-19 Vaccination.

Journal: SN comprehensive clinical medicine
Published: September 01, 2021
Showing 1-12 of 27

Last Updated: 09/26/2026